Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
Stefano LuminariMartina ManniSara GalimbertiAnnibale VersariAlessandra TucciCarola BoccominiLucia FarinaJacopo OlivieriLuigi MarcheselliLuca GuerraSimone FerreroLuca ArcainiFederica CavalloSofya KovalchukTetiana SkrypetsIlaria Del GiudiceStephane ChauvieCaterina PattiCaterina StelitanoFrancesca RicciAntonello PintoGloria Margiotta CasaluciVittorio Ruggero ZilioliAnna MerliMarco LadettoSilvia BolisVincenzo PavoneAnnalisa ChiarenzaAnnalisa ArcariAntonella AnastasiaAlessandra DondiDonato ManninaMassimo Federiconull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
A metabolic and molecular response-adapted therapy as assessed in the FOLL12 study was associated with significantly inferior PFS compared with 2-year RM. The better efficacy of standard RM was confirmed in the subgroup analysis and particularly for patients achieving both CMR and MRD-negative.